USA flag logo/image

An Official Website of the United States Government

li Suppression-enhanced HIV DNA Vaccine

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66025
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AI054149
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANTIGEN EXPRESS, INC.
ANTIGEN EXPRESS, INC. 100 BARBER AVE WORCESTER, MA 01606
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: li Suppression-enhanced HIV DNA Vaccine
Agency: HHS
Contract: 1R43AI054149-01
Award Amount: $354,100.00
 

Abstract:

DESCRIPTION (provided by applicant): Antigen Express scientists have discovered that cells expressing MHC class II molecules in the absence of the MHC class II-associated Ii protein can act as effective cellular vaccines. Cells with the MHC class II+/Ii-phenotype simultaneously present endogenously synthesized antigens by both MHC class I and class II molecules to CD8+ and CD4+ T cells, respectively. When the Ii protein does not block the MHC class II molecules at synthesis, the epitope pool available for MHC class I is also available for presentation by MHC class II molecules, leading to the creation of very potent vaccine cells. In this SBIR, we will use our Ii-suppression technology to augment the efficacy of HIV DNA vaccines. We will: 1) clone the HIV gp120 gene into vectors containing our Ii-reverse gene construct. Dendritic cells that take up the vector will then both synthesize gp120 and form the MHC class II+/Ii-phenotype; 2) identify optimal routes of inoculation and delivery agents for the in vivo transfection of lymph node lymphocytes and dendritic cells and, 3) characterize the in vivo ability of Ii-RGC/gp120 containing vectors versus gp120 alone to generate gp120-specific T cell proliferation and gp120-specific CTL activity. Our experiments will establish the potential utility of developing Ii-RGC/gp120 DNA vectors as HIV vaccines in the clinic. In a Phase II program Ii-RGC/gp120 DNA vaccines will be tested in non-human primates for the induction of a protective immune response against pathogenic HIV infection.

Principal Investigator:

Minzhen Xu
5088528783
ANTIGENEXP@AOL.COM

Business Contact:

Robert Humphreys
5088528801
ANTIGENEXP@AOL.COM
Small Business Information at Submission:

ANTIGEN EXPRESS, INC.
ANTIGEN EXPRESS, INC. 100 BARBER AVE WORCESTER, MA 01606

EIN/Tax ID: 043208418
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No